Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relenza Studies In High-Risk Populations Might Show More Efficacy - Cmte.

Executive Summary

Additional studies of Glaxo Wellcome's Relenza Diskhaler should be targeted to specific high-risk populations in order to more clearly show efficacy of zanamivir against influenza, members of FDA's Antiviral Drugs Advisory Committee said Feb. 24.

You may also be interested in...



Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%

A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel